These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

355 related articles for article (PubMed ID: 22369442)

  • 1. Emerging and second line therapies for the management of metastatic castration-resistant prostate cancer: the Australian perspective.
    Parente P; Parnis F; Gurney H
    Asia Pac J Clin Oncol; 2012 Mar; 8(1):31-42. PubMed ID: 22369442
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New and emerging agents for the treatment of castration-resistant prostate cancer.
    Higano CS; Crawford ED
    Urol Oncol; 2011; 29(6 Suppl):S1-8. PubMed ID: 22074657
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cabazitaxel for the treatment of prostate cancer.
    Michielsen DP; Braeckman JG; Denis L
    Expert Opin Pharmacother; 2011 Apr; 12(6):977-82. PubMed ID: 21406025
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical roundtable monograph: new and emerging treatments for advanced prostate cancer.
    George DJ; Kantoff PW; Lin DW
    Clin Adv Hematol Oncol; 2011 Jun; 9(6):1-11; discussion 11-5. PubMed ID: 21941983
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Landmarks in non-hormonal pharmacological therapies for castration-resistant prostate cancer.
    Clarke NW
    BJU Int; 2012 Oct; 110 Suppl 1():14-22. PubMed ID: 23046036
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current and emerging treatments in the management of castration-resistant prostate cancer.
    Shapiro D; Tareen B
    Expert Rev Anticancer Ther; 2012 Jul; 12(7):951-64. PubMed ID: 22845410
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emerging therapies in metastatic castration-sensitive and castration-resistant prostate cancer.
    MacVicar GR; Hussain MH
    Curr Opin Oncol; 2013 May; 25(3):252-60. PubMed ID: 23511665
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chemotherapy-based treatment for castration-resistant prostate cancer.
    Seruga B; Tannock IF
    J Clin Oncol; 2011 Sep; 29(27):3686-94. PubMed ID: 21844499
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Castration-resistant prostate cancer: where are we going?].
    Alcaraz A; Medina R; Maroto P; Climent MÁ; Castellano D; Carles J
    Actas Urol Esp; 2012 Jun; 36(6):367-74. PubMed ID: 22188754
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent advances in second-line treatment of castration-resistant prostate cancer.
    Ong M; Winquist E
    Curr Opin Support Palliat Care; 2011 Sep; 5(3):199-205. PubMed ID: 21734586
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cabazitaxel for the treatment of castration-resistant prostate cancer.
    Agarwal N; Sonpavde G; Sartor O
    Future Oncol; 2011 Jan; 7(1):15-24. PubMed ID: 21174534
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metastatic castration resistant prostate cancer: current strategies of management in the Middle East.
    Bazarbashi S; Bachour M; Bulbul M; Alotaibi M; Jaloudi M; Jaafar H; Mukherji D; Farah N; Alrubai T; Shamseddine A
    Crit Rev Oncol Hematol; 2014 Apr; 90(1):36-48. PubMed ID: 24289901
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment options in castration-resistant prostate cancer: current therapies and emerging docetaxel-based regimens.
    Saad F; Miller K
    Urol Oncol; 2014 Feb; 32(2):70-9. PubMed ID: 23506965
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systemic therapy after first-line docetaxel in metastatic castration-resistant prostate cancer.
    Beardsley EK; Chi KN
    Curr Opin Support Palliat Care; 2008 Sep; 2(3):161-6. PubMed ID: 18685415
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New therapies for castration-resistant prostate cancer: efficacy and safety.
    Beltran H; Beer TM; Carducci MA; de Bono J; Gleave M; Hussain M; Kelly WK; Saad F; Sternberg C; Tagawa ST; Tannock IF
    Eur Urol; 2011 Aug; 60(2):279-90. PubMed ID: 21592649
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Progress in emerging therapies for advanced prostate cancer.
    Oudard S
    Cancer Treat Rev; 2013 May; 39(3):275-89. PubMed ID: 23107383
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel therapeutics for the management of castration-resistant prostate cancer (CRPC).
    Lee DJ; Cha EK; Dubin JM; Beltran H; Chromecki TF; Fajkovic H; Scherr DS; Tagawa ST; Shariat SF
    BJU Int; 2012 Apr; 109(7):968-85. PubMed ID: 22035221
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Prostate cancer and chemotherapy: standards care and perspectives].
    Hadjarab Y; Oudard S
    Bull Cancer; 2012 Jul; 99 Suppl 1():S46-56. PubMed ID: 22516516
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Second-line treatment options in metastatic castration-resistant prostate cancer: a comparison of key trials with recently approved agents.
    Bahl A; Masson S; Birtle A; Chowdhury S; de Bono J
    Cancer Treat Rev; 2014 Feb; 40(1):170-7. PubMed ID: 23958310
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Zibotentan for the treatment of castrate-resistant prostate cancer.
    Shepard DR; Dreicer R
    Expert Opin Investig Drugs; 2010 Jul; 19(7):899-908. PubMed ID: 20497097
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.